CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studies The European Commission is […]
severe
Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first […]
Coronavirus deals severe blow to services sectors
Personal services sectors such as tourism, hospitality and retail at a standstill due to drastic measures taken in the fight against COVID-19. The COVID-19 pandemic […]